In silico ranking of phenolics for therapeutic effectiveness on cancer stem cells

Monalisa Mandal¹, Sanjeeb Kumar Sahoo², Priyadarshan Patra¹, Saurav Mallik³ and Zhongming Zhao³,4*

From The International Conference on Intelligent Biology and Medicine (ICIBM) 2020 Virtual. 9-10 August 2020

Abstract

Background: Cancer stem cells (CSCs) have features such as the ability to self-renew, differentiate into defined progenies and initiate the tumor growth. Treatments of cancer include drugs, chemotherapy and radiotherapy or a combination. However, treatment of cancer by various therapeutic strategies often fail. One possible reason is that the nature of CSCs, which has stem-like properties, make it more dynamic and complex and may cause the therapeutic resistance. Another limitation is the side effects associated with the treatment of chemotherapy or radiotherapy. To explore better or alternative treatment options the current study aims to investigate the natural drug-like molecules that can be used as CSC-targeted therapy. Among various natural products, anticancer potential of phenolics is well established. We collected the 21 phytochemicals from phenolic group and their interacting CSC genes from the publicly available databases. Then a bipartite graph is constructed from the collected CSC genes along with their interacting phytochemicals from phenolic group as other. The bipartite graph is then transformed into weighted bipartite graph by considering the interaction strength between the phenolics and the CSC genes. The CSC genes are also weighted by two scores, namely, DSI (Disease Specificity Index) and DPI (Disease Pleiotropy Index). For each gene, its DSI score reflects the specific relationship with the disease and DPI score reflects the association with multiple diseases. Finally, a ranking technique is developed based on PageRank (PR) algorithm for ranking the phenolics.

Results: We collected 21 phytochemicals from phenolic group and 1118 CSC genes. The top ranked phenolics were evaluated by their molecular and pharmacokinetics properties and disease association networks. We selected top five ranked phenolics (Resveratrol, Curcumin, Quercetin, Epigallocatechin Gallate, and Genistein) for further examination of their oral bioavailability through molecular properties, drug likeness through pharmacokinetic properties, and associated network with CSC genes.

Conclusion: Our PR ranking based approach is useful to rank the phenolics that are associated with CSC genes. Our results suggested some phenolics are potential molecules for CSC-related cancer treatment.

Keywords: Phenolics, Cancer stem cell, Bipartite graph, Page rank

*Correspondence: Zhongming.Zhao@uth.tmc.edu
³ Center for Precision Health, School of Biomedical Informatics, The University of Texas Health Science Center At Houston, Houston, TX 77030, USA
Full list of author information is available at the end of the article
Background

Cancers diagnosed at the earlier stage can be curable through conventional treatments such as surgery, chemotherapy and radiotherapy [1–4]. However, cancers diagnosed at a later stage are more progressive and aggressive and they often lead to metastasis to multiple organs. While significant progress has been made to improve diagnosis and surveillance, this has not helped much to improve the overall cancer survival rates [5, 6]. Even after the cancer is diagnosed and treated at earlier stage, not all cancer cells can be killed and tumor recurrence has been frequently reported. When tumor recurrence happens, cancer becomes more aggressive and metastatic [7–9]. Growing evidences [10–12] has indicated that these residual cells play a crucial role as therapeutic resistant and own the property of self-renewal (stem-like properties) known as the cancer stem cells (CSCs). CSCs behave same as normal stem cells do. Moreover, they have multi-differentiative potentials and capability of generating multiple cancer cell types that eventually develop tumors. The self-renewal property of CSCs enables them to give rise to other type malignant cells [13, 14]; therefore, they can be described as phenotypically and functionally diversified immortal tumor cells. Such cells have been found in various types of human tumors and might be attractive targets for cancer treatment [11, 12, 15–17]. These CSCs generally make up just 1% to 5% of all cells in a tumor [18]. Most CSCs are believed to be resistant to chemo- or radio-therapy, indicating CSCs play an important role in cancer relapse and metastasis. Therefore, it requires the development of novel, diverse, and multi-targeted approaches for cancer treatment due to the fact that CSCs have different and still uncovered characteristics. But in fact, clinicians are still struggling to find such CSC targeting therapies with no or limited side-effects.

The currently available treatment options for cancer are surgery, radiation therapy and chemotherapy. More recently, systemic chemotherapy [2, 19–21] has becoming the popular one for cancer treatment. Along with cancer cells, healthy cells are also damaged by chemotherapeutic drugs. This may cause side effects to the patients. Lack of major progresses in molecular targeted therapies has made researchers to unfold the prospects of natural anticancer agents from plants known as phytochemical. During the years, phytochemicals are a major topic of research because of their naturally healing capability. For the disease such as cancer, they have been testified for having the potential to target heterogeneous populations of cancer cells and CSCs. Moreover, they are capable of targeting the key signaling pathways of cancer leaving the normal cells intact or minimal toxicity. However, laboratory-based experiments for identifying the drug targets for natural products is not only expensive, labor expensive, but also a prolonged process. Therefore, computational approaches for drug (phytochemical) ranking can greatly speed up the traditional drug discovery process [15, 22], and can provide potential candidates for follow up experimental validation. To date, there have been strong needs to develop a systematic and comprehensive computation-based approaches to identify and validate phytochemical for cancer cells.

In this study, CSC genes and their interacting phytochemicals from the phenolic group are systematically collected and curated from the available databases. Then, a bipartite graph has been built from the collected data where CSC genes form one disjoint independent set and the interacting phytochemical is the other set. The graph is then weighted according to the interaction strength between the phenolics and the CSC.
genes. Two different metrics have been used to weight the CSC genes: \( DSI \), which indicates the extent of a gene being specific to a disease, and \( DPI \) which indicates the association of a gene with a set of diseases (pleiotropy). After forming the weighted bipartite graph, a ranking technique based on PageRank (PR) has been applied to rank the phenolics signifying their influence on the CSC genes. Different datasets and platforms are used to validate the resultant phenolics.

**Methods**

CSCs, like all stem cells, are unspecialized and can divide and renew themselves, as well as give rise to specialized cells. This type of stem cells can be found in a small proportion within a tumor and can replicate tumor cells. Thus, they may lead to tumor growth and migration. They can be left behind even after the course of cancer treatment completes, allowing the tumor to recur and spread around the body. Natural products may be the one reliable option to discover novel treatments demanded by the difficulty of treating CSCs. The work on CSCs is still in early stages. Currently, the research on CSCs is primarily taking place in the research laboratory. Early clinical trials are targeted in the development of effective anti-cancer strategies. As the number of the experiments is few; therefore, the CSC related databases [23] are also rare. Moreover, those databases have little CSC related information.

**CSC related genes data**

We collected 1118 CSC related genes from the CSCdb database [23]. CSCdb is a literature-based database (collected from about 13,000 articles) and useful for CSC-related research. The database contains CSCs marker genes, CSCs-related genes and their functional annotations. It could be an important resource for finding new CSCs and their potential therapeutic targets. A complete information of 1769 genes that have been found to be associated in the functional regulation of CSCs is provided by CSCdb. In addition, 74 marker genes along with 9475 annotations on 13 CSC-related functions have been reported.

**Phenolics data**

In addition to the common cancer treatments (surgery, radiotherapy and chemotherapy), the systemic chemotherapy has become an alternative cancer treatment. Two common problems associated with chemotherapy are drug resistance and toxicity by damaging healthy cells, causing them to secret proteins that accelerates the growth of cancer and develop drug resistance in patients. To address these limitations of cytotoxic chemotherapy, researchers are keenly interested in natural products as some recent studies proved their chemo-protective properties such as anticancer properties [15]. Natural therapies, such as the use of plant-derived products in cancer treatment, may reduce adverse side effects. Currently, a few plant products are being used to treat cancer. The list of phytochemicals is collected from the literatures [24, 25]. There are different group of phytochemical available from different natural products. In this paper, only 21 phenolics are considered for the study. The list of phenolics are given in Table 1. We then searched these 21 phenolics in the PCIDB database [26]. For each of the phenolic, the interacting genes are collected. Moreover, the numbers that a phenolic interacting with a
gene are also downloaded in the same way. From the literatures [22, 24, 27], satisfactory clinical instances are achieved for Allium sativum, camptothecin, curcumin, green tea, Panax ginseng, resveratrol, Rhus verniciflua and Viscum album dence to support their anticancer effects. The experiments on natural products clearly show that they can be used as complementary therapeutics against various types of cancer.

### DisGeNet

DisGeNet is a database that yields scores to the genes depending on various metrics [28]. Here, the DSI and DPI scores for each gene are considered. The DSI score of a gene indicates how much a gene is specific to a disease. For example, if a gene is associated with too many diseases, DSI score for that gene is as low as 0. On the other hand, if a gene is associated with only one or few diseases, its DSI score would be as high as 1. It is calculated as Eq. 1:

\[
DSI = \frac{\log_2(N_d/N_T)}{\log_2(1/N_T)},
\]

where \(N_d\) is the number of diseases associated to the gene and \(N_T\) is the total number of diseases in DisGeNet. The DPI score for a gene is 1 if it is associated with largely different classes of diseases and 0 if it is associated with same class of diseases. It is calculated according to Eq. 2.

| Sl # | Phenolic | Chemical formula | Sources |
|------|----------|------------------|---------|
| 1    | Curcumin | C21H20O6         | Turmeric |
| 2    | Gossypol | C30H30O8         | Cotton Plant |
| 3    | 6-Shogaol | C17H24O3        | Ginger |
| 4    | 6-Gingerol | C17H26O4     | Ginger |
| 5    | Apigenin | C15H10O5        | parsley, celery, rosemary, coriander, cloves, spinach |
| 6    | Baicalein | C15H10O5     | Scutellaria Baicalein, Scutellaria lateriflora |
| 7    | Cyanidin | C15H11O6        | cranberries |
| 8    | Delphinidin | C15H11O7   | Grapes, Cran berries, Corn cord grapes, Pomegranates |
| 9    | Embelin  | C17H26O4        | Japanese Ardisia herb |
| 10   | Epigallocatechin | C22H18O11 | Green Tea |
| 11   | Fisetin  | C15H10O6        | strawberry, apple, grapes, onion, cucumber |
| 12   | Genistein | C15H10O5     | Fara beans, Soybeans, Psoralea Flemingia vestita, F.macrophylla, Coffe |
| 13   | Glabridin | C20H20O4        | licorice(root extract) |
| 14   | Isoliquiritigenin | C15H12O4 | Root of licorice (Glycyrrhiza uralensis) |
| 15   | Luteolin  | C15H10O6        | Cabbage, spinach, peppers |
| 16   | Pterostilbene | C16H16O3 | Blueberries, almond, mulberries |
| 17   | Quercetin | C15H10O7        | Fruits, Vegetables, Leaves and Grains |
| 18   | Resveratrol | C14H12O3    | red and purple grapes, blueberries, cranberries, mulberries, peanuts, roots of Japanese knotweed |
| 19   | Rosmarinic | C18H16O8     | rosemary, lemon balm, sage, basil |
| 20   | Silibinin | C25H22O10       | Extract of Milk thistle seeds |
| 21   | Psoralidin | C20H16O5     | Seeds of Psoralea corylifolia |
\[ DPI = \left( \frac{N_{dc}}{N_{TC}} \right) \times 100, \]  

(2)

where \( N_{dc} \) is the number of the different MeSH disease classes of the diseases associated to the gene and \( N_{TC} \) is the total number of MeSH diseases classes in DisGeNet.

**PageRank (PR)**

PR invented by Google founders Larry Page and Sergey Brin, is a way of measuring the importance of website pages [29]. PR is an algorithm used by Google Search to rank websites in their search engine results. Essentially, PR does not rank web sites as a whole, but is determined for each page individually. Further, the PR of page A is recursively defined by the PR of those pages which link to page A. When site A links to any web page, Google considers this as site A endorsing, or casting a vote for that page. Google takes into consideration all of these link votes (i.e., the website’s link profile) to draw conclusions about the relevance and significance of individual webpages and your website as a whole. This is the basic concept behind PR. In short, PR is “vote” by all the other pages on the Web regarding how important a page is. A link to a page counts as a vote of support. When there is no link, it means no support (but it is an abstention from voting rather than a vote against the page). From the original Google paper [29], PR has been defined as in Eq. 3.

\[ PR(A) = (1 - d) + d \frac{PR(T1)}{C(T1)} + ... + \frac{PR(Tn)}{C(Tn)}, \]  

(3)

where \( PR(A) \) is the PR of page A, \( PR(T_i) \) is the PR of pages \( T_i \) which links to page A, \( C(T_i) \) is the number of outgoing links on page \( Ti \) as each page spreads its vote out evenly amongst all outgoing links. The number of outgoing links for page 1 is \( C(T_1) \), \( C(T_n) \) for page \( n \), and so on for all pages, and \( d \) is a damping factor which can be set between 0 and 1. They usually set \( d \) to 0.85. Note that the PR form a probability distribution over pages, so the sum of all web pages’ PR will be 1. PR or PR(A) can be calculated using a simple iterative algorithm, which corresponds to the principal eigenvector of the normalized link matrix of the web.

PR or PR(A) can be calculated using a simple iterative algorithm, and corresponds to the principal eigenvector of the normalized link matrix of the web. That means just calculating a page’s PR without knowing the final value of the PR of the other pages. Basically, in each run, the calculation is getting closer to estimate the final value. So, repeat the calculations many times until the numbers stop changing by a threshold value.

**Preprocessing of the dataset**

Assume that \( p = \{p_1, p_2, ..., p_m\} \) is a list of the phenolics whose set of interacting genes are \( G_p = \{G_{p1}, G_{p2}, ..., G_{pm}\} \), where \( G_{p1}, G_{p2}, ..., G_{pm} \) is the gene set that interacts with \( p_1, p_2, ..., p_m \) respectively. CSC genes are collected from CSCdb database. Suppose \( q \) CSC genes are collected and described as \( CSC = \{cg_1, cg_2, ..., cg_q\} \). We then take the common genes between each interacting set and CSC gene set and it generates \( G_{p1} \cap CSC, G_{p2} \cap CSC, ..., G_{pm} \cap CSC \) and it implies \( G_1, G_2, ..., G_m \) if \( G_{p1} \cap CSC = G_1, G_{p2} \cap CSC = G_2, ..., \) etc.
Next, out of these gene sets, the common gene set \( s \) is taken out and then these genes are searched in DisGeNet database for collecting their score. A few of them do not have scores; therefore, they are excluded from the set. Finally, \( n \) genes (<\( s \)) are gathered for further processing.

**Proposed method**

From the collected datasets, a weighted bipartite graph is constructed where one set of the bipartite graph is the set of phenolics (i.e., \( p \)) and other set is the gene set (i.e., \( n \)). The edges are weighted according to the number of ways a phenolic interacting with the genes. These weights are normalized by using mean and standard deviation. The absolute of the normalized values are taken into consideration. The \( n \) genes are also weighted in terms of DSI and DPI scores. Given the above weighted bipartite graph, the job of the algorithm is to rank the phenolics. Here, it comes the concept of Page Ranking that has been used to build our model. Starting with a random ranking for the phenolics, the edge weights and gene weights are used to recalculate the new ranks and gradually conclude the final ranks for the phenolics. The critical question is when to stop recalculating the ranks for the phenolics. The answer is kept on calculating the ranks for the phenolics until no change is found in the last two rankings. The pictorial definition of the proposed method has been shown in Fig. 1.

Rank calculation: Let \( p_1 \) is the phenolic for which a random rank \( r_1 \) is given initially. A random value between 0 and 1 has been generated for each phenolic. When these values are sorted in non-increasing order, they will produce the rankings for the phenolics. So, \( r_1 \) is the value in between 0 and 1. If phenolic \( p_1 \) interacts with \( x \) genes with edge weights \( w_1, w_2, ..., w_x \) and \( x \) genes have the weights \( gw_1, gw_2, ..., gw_x \) given by DSI and DPI, then the new rank of phenolic \( p_1 \) is calculated as

\[
    r_{new} = r_1 \sum_{i=1}^{x} w_i * gw_i / \text{abs(normalized}(x))
\]

**Results and discussion**

Among 21 phenolics, the top five phenolics are Resveratrol, Curcumin, Quercetin, Epi-gallocatechin Gallate and Genistein. For demonstration purpose, only these top ranked phenolics are studied for their oral bioavailability through molecular properties, drug likeness through pharmacokinetic properties and associated net-work with CSC genes.

**Calculation of molecular properties**

All the calculated parameters, namely molecular weight, log P, the number of rotatable bonds, polar surface area, the number of hydrogen bond donors and acceptors, the Lipsinski Rule violation, aromatic rings and heavy atoms, are thought to be associated with molecular flexibility, oral bioavailability, solubility and permeability of drugs which are the basic requirements for any drug to have good pharmacokinetic parameters. These properties are calculated from ChEMBL, a large bioactivity
The molecular weight describes the molecular flexibility and oral bioavailability. As summarized in Table 2, the molecular weights for all the five phenolics are 228.25, 368.39, 302.24, 458.38 and 270.24, respectively. This information indicates that the top ranked phenolics have high molecular flexibility as well as oral bioavailability. It has been seen that the molecular flexibility correlates with molecular weight, that is, larger compounds would be more flexible. The logP is lipophilicity of a compound and for all the five phenolics, logP values are greater than or equal to 2, but less than 5. The numbers of rotatable bond are defined as any single bond, not in a ring, bound to a nonterminal heavy atom (i.e., non-hydrogen). It can be seen the majority of compounds with seven or fewer rotatable bonds met which represents more oral bioavailability as published in the literature [31]. As Polar Surface Area (PSA) characterizes drug absorption, including intestinal absorption and bioavailability, therefore the five phenolics have high PSA, specially Epigallocatechin Gallate (197.37) as PSA. From literature [31], it has been established that 12 or fewer Hydrogen Bond (H-Bond) Acceptors (HBA) and H-Bond Donors (HBD) are essentially good for those with high oral bioavailability. In this study we found top ranked phenolics have less than 12 HBAs and HBDs. Lipinski rule of 5 based on five criteria namely, molecular mass, high lipophilicity (logP), hydrogen bond donors, hydrogen bond acceptors and molar refractivity. Except for Epigallocatechin Gallate, no top ranked phenolics are violated the Lipinski rule of 5. It has been well established that more than three aromatic rings in a molecule correlate with poorer drug development ability [32]. All the top five phenolics have 3 or fewer aromatic rings, indicating their druggability.

### Phytochemical and structural properties

**Resveratrol**

The phytochemical compound is stilbenoids. A stilbenol is stilbene in which the phenyl groups are substituted at positions 3, 5, and 4′ by hydroxy groups. The chemical structure of resveratrol is given in Fig. 2. It has anticancer properties and inhibits lipid peroxidation of low-density lipoprotein and prevents the cytotoxicity of oxidized LDL [33]. Resveratrol also increases the activity of some antiretroviral drugs in vitro.
Curcumin
The phytochemical compound is Diarylheptanoids. A beta-diketone is methane in which two of the hydrogens are substituted by feruloyl groups. A natural dyestuff is found in the root of Curcuma longa. Curcumin has antioxidant, anti-inflammatory, antiviral and antifungal actions [34, 35]. The chemical structure of curcumin is given in Fig. 3.

Quercetin
The phytochemical compound is flavonoid. A pentahydroxyflavone has the five hydroxy groups placed at the 3-, 3′-, 4′-, 5- and 7-positions. It is one of the most abundant flavonoids in edible vegetables, fruit and wine. Health effects include an improvement of cardiovascular health, reducing risk for cancer, and protection against osteoporosis. This phytochemical has anti-inflammatory, anti-allergic and antitoxic effects [36]. The chemical structure of quercetin is shown in Fig. 4.

Epigallocatechin gallate
The phytochemical compound is Flavan 3-ols flavan. A gallate ester obtained by the formal condensation of gallic acid with the (3R)-hydroxy group of (-)-epigallocatechin. A number of chronic diseases have been associated with free radical damage, including cancer, arteriosclerosis, heart diseases and accelerated aging [37]. Epigallocatechin gallate interferes with many enzyme systems: it inhibits fast-binding and reversible fatty acid synthase, increases tyrosine phosphorylation of the insulin receptor, activation of ornithine decarboxylase. The chemical structure of epigallocatechin gallate is given in Fig. 5.

Genistein
The phytochemical compound is Isoflavones, 7-Hydroxyisoflavone with additional hydroxy groups at positions 5 and 4′. It is a phytoestrogenic isoflavone with antioxidant properties. It acts as a phytoestrogenic, antioxidant, anti-cancer agent and it could help people with metabolic syndrome [38]. The chemical structure of genistein is given in Fig. 6.

Drug likeliness analysis
The pharmacokinetic properties of a chemical present the drug-like ability of a molecule. Therefore, it is an important aspect in consideration. These pharmacokinetic properties are calculated in pkCSM platform [39]. Water Solubility of a compound (logS) reflects the solubility of the molecule in water at 25°C and given as the logarithm of the molar concentration logmol/L. A compound is considered to have high Caco-2 permeability if it has a \( P_{app} > 8 \times 10^{-6} \text{ cm/s} \). High Caco-2 permeability would be for a predicted value > 0.90. From Table 3, it is clear that most of them are greater than 0.90 as Caco-2 permeability. For a given compound, the intestinal absorption predicts the percentage that will be absorbed through the human intestine. A molecule with an absorbance of less than 30% is considered to be poorly absorbed. All the top five ranked phenolics from our experiment have intestinal absorption values
### Table 3  ADME profile for the top five phenolics

| Phenolic             | Water solubility log(mol/L) | Caco-2 permeability $10^6$ cm/s | Intestinal Absorption (human) % absorbed | Skin permeability Area logKp | BBB permeability logBB | CNS permeability logPS | Max. dose (human) log mg/day | Hepato-toxicity | Skin sensation | T. Pyri-formis toxicity log ug/L | Minnow toxicity log mM |
|----------------------|-----------------------------|---------------------------------|------------------------------------------|-----------------------------|-----------------------|------------------------|--------------------------|-----------------|----------------|-----------------------------|------------------------|
| Resveratrol          | −3.192                      | 1.191                           | 890.57                                   | −3.16                       | −0.041                | −20.98                 | 0.486                    | No              | No             | 1.072                       | 0.342                  |
| Curcumin             | −4.208                      | 0.55                            | 856.52                                   | −2.744                      | −0.992                | −29.59                 | −0.219                   | No              | No             | 0.372                       | −0.631                 |
| Quercetin            | −3.17                       | 0.162                           | 74.535                                   | −2.735                      | −1.461                | −33.74                 | 0.983                    | No              | No             | 0.317                       | 0.943                  |
| Epigallocatechin gallate | −2.893                  | −0.721                          | 58.337                                   | −2.735                      | −2.363                | −44.07                 | 0.473                    | No              | No             | 0.285                       | 3.239                  |
| Genistein            | −3.415                      | 1.019                           | 93.39                                    | −2.737                      | −0.979                | −21.56                 | 0.709                    | No              | No             | 0.528                       | 5.12                   |
greater than 30%. A compound is considered to have a relatively low skin permeability if it has $\log K_p > -2.5$. The outcome of our experiment shows that all the top five ranked phenolics have $\log K_p > -2.5$. The ability of a drug to cross the brain is an important measure to reduce the side effects. Blood–Brain permeability is measured as the logarithmic ratio of the brain to plasma drug concentration ($\log BB$). For a given compound, a $\log BB > 0.3$ has been treated as readily cross the blood–brain-barrier (BBB) while molecules with $\log BB < -1$ are poorly distributed to the brain. The results from the table indicate that except Quercetin and Epigallocatechin Gallate, the rest three phenolics have good BBB values which are $-0.041$, $-0.992$ and $-0.979$. They have same for the Central Nervous System (CNS) permeability. The maximum recommended tolerated dose provides an estimate of a toxic dose threshold of chemicals in humans. Hepatoxide predicts whether a given compound is likely to be associated with disrupted normal function of the liver. Skin sensation indicates whether the compound is skin sensitive. All the top five phenolics are neither hepatoxic nor skin sensitive. Another toxicity measure is T. Pyriformis value, which is considered toxic if the predicted value is greater than $-0.5 \log \mu g/L$. The T.Pyriformis values of all the top phenolics are $(1.072, 0.372, 0.317, 0.285$ and $0.528)$ greater than $-0.5 \log \mu g/L$. The predicted Minnow toxicity value is regarded as high acute toxicity if it is below $0.5 \text{ mM} (\log LC_{50} < -0.3)$. It is evident that the top five phenolics are not Minnow toxic (Table 3).

**Association with CSC genes**

To find the association between the top ranked phenolics and CSC genes, the Comparative Toxicogenomics Database (CTD) [40] has been used. As shown in Table 4, a majority of them are associated with prostatic neoplasms, breast neoplasms, carcinoma hepatocellular, stomach neoplasms, and colorectal neoplasms, as sorted by their inference score. The table also shows the association between phenolics and diseases (neoplasms class) by interacting with the cancer genes in the inference network and CSC genes that has also been tabularized. Then the inference score of the network and references are collected from the CTD database. It has been noticed that all the phenolics interact with the highest number of CSC genes of Breast neoplasms. Biological relevance of the top rank phenolics are also described in Table 5. To find biological relevance computationally, top ten interacting genes, top five pathways with $p$-value and top five GO terms with $p$-value are collected from CTD database. It is clear from the table that most of the top interacting genes are cancer related, however it is still unknown whether they are also CSCs related. However, there are many works conducted regarding the combinations of the drugs targeting different CSC-genes [41–44].

The total experiment has been done computationally. From dataset collection to validating the top ranked phenolics, our results relied on the information from different databases and literatures. However, we will extend the study not only on CSC related genes but their druggability in future.
### Table 4 Phenolics-diseases association network analysis

| Phenolic        | Disease                  | # genes inference network | # CSC genes inference network | Inference score | # Ref |
|-----------------|--------------------------|---------------------------|------------------------------|-----------------|-------|
| Resveratrol     | Prostatic Neoplasms      | 291                       | 131                          | 328.99          | 252   |
|                 | Prostatic Carcinoma      | 270                       | 116                          | 324.69          | 125   |
|                 | Breast Neoplasms         | 280                       | 171                          | 273.85          | 305   |
|                 | Prostatic Hepatocellular | 134                       | 86                           | 145.65          | 115   |
|                 | Colorectal Neoplasms     | 125                       | 74                           | 140.51          | 103   |
| Curcumin        | Breast Neoplasms         | 153                       | 122                          | 247.14          | 208   |
|                 | Prostatic Neoplasms      | 136                       | 94                           | 217.95          | 192   |
|                 | Prostatic Carcinoma      | 117                       | 77                           | 186.10          | 84    |
|                 | Breast Neoplasms         | 83                        | 63                           | 147.58          | 69    |
|                 | Breast Neoplasms         | 81                        | 66                           | 146.98          | 78    |
| Quercetin       | Prostatic Neoplasms      | 265                       | 111                          | 304.07          | 120   |
|                 | Prostatic Carcinoma      | 274                       | 135                          | 283.06          | 233   |
|                 | Breast Neoplasms         | 260                       | 154                          | 236.81          | 289   |
|                 | Stomach Neoplasms        | 144                       | 81                           | 153.43          | 86    |
|                 | Colorectal Neoplasms     | 124                       | 70                           | 134.19          | 108   |
| Epigallocatechin Gallate | Prostatic Neoplasms   | 142                       | 75                           | 133.23          | 160   |
|                 | Carcinoma Neoplasms      | 119                       | 61                           | 108.13          | 84    |
|                 | Breast Neoplasms         | 128                       | 87                           | 96.20           | 189   |
|                 | Stomach Neoplasms        | 75                        | 49                           | 73.46           | 59    |
|                 | Colorectal Neoplasms     | 64                        | 43                           | 63.29           | 67    |
| Genistein       | Prostatic Neoplasms      | 236                       | 123                          | 285.98          | 236   |
|                 | Breast Neoplasms         | 206                       | 167                          | 199.41          | 232   |
|                 | Carcinoma Neoplasms      | 202                       | 98                           | 241.78          | 106   |
|                 | Hepatocellular Neoplasms | 122                       | 76                           | 149.43          | 69    |
|                 | Lung Neoplasms           | 111                       | 84                           | 98.88           | 133   |
| Phenolic     | Top 10 interacting genes                      | Top 5 pathways (p-value)                                                                                                         | Top 5 GO terms (p-value)                                                                 |
|-------------|----------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|
| Resveratrol | TNF, SIRT1, IL1B, CASP3, PTGS2, IL6, TP53, RELA, MAPK1, MAPK3 | Metabolism–REACT:R-HSA-1430728 (4.90e–324), immune system–REACT:R-HSA-168256 (7.89e–284), signal transduction–REACT:R-HSA-162582 (7.46e–256), innate immune system–REACT:R-HSA-168249 (4.62e–202), metabolic pathways–KEGG:hsa01100 (1.20e–176) | BP: positive regulation of cytosolic calcium ion concentration (2.62e–34), BP: glucose import (9.96e–25), BP: cytosolic calcium ion transport (1.94e–24), BP: internal peptidyl-lysine acetylation (1.00e–17), MF: E-box binding (3.34e–15) |
| Curcumin    | TNF, HMOX1, NFE2L2, BCL2, RELA, CASP3, PTGS2, IL1B, IL6, BAX | Immune system–REACT:R-HSA-168256 (3.15e–178), innate immune system–REACT:R-HSA-168249 (3.11e–143), signal transduction–REACT:R-HSA-162582 (2.18e–142), pathways in cancer–KEGG:hsa05200 (2.08e–141), cytokine signaling in immune system–REACT:R-HSA-1280215 (1.24e–122) | BP: positive regulation of cytosolic calcium ion concentration (1.78e–20), BP: cytosolic calcium ion transport (3.15e–14), BP: glucose import (1.14e–13), BP: activation of protein kinase B activity (1.66e–12), BP: T-helper cell differentiation (8.13e–12) |
| Quercetin   | TNF, CASP3, HMOX1, IL1B, NOS2, MAPK3, NFE2L2, MAPK1, BCL2, AKT1 | Immune system–REACT:R-HSA-168256 (6.77e–271), signal transduction–REACT:R-HSA-162582 (1.81e–247), metabolic pathways–KEGG:hsa01100 (9.34e–193), innate immune system–REACT:R-HSA-168249 (1.30e–178), pathways in cancer–KEGG:hsa05200 (1.96e–144) | BP: positive regulation of cytosolic calcium ion concentration (1.63e–23), BP: glucose import (7.99e–22), BP: cytosolic calcium ion transport (4.09e–16), BP: protein polyubiquitination (1.81e–14), BP: internal peptidyl-lysine acetylation (1.80e–12) |
| Epigallocatechin gallate | ARNTL, AKT1, BDNF, CAT, CREB1, SOD1, BNIP3, CLOCK, COX2, COX4 | Tuberculosis–KEGG:hsa05152 (1.03e–21), Hepatitis B–KEGG:hsa05161 (5.22e–21), Non-alcoholic fatty liver disease (NAFLD)–KEGG:hsa04932 (8.26e–21), AGE-RAGE signaling pathway in diabetic complications–KEGG:hsa04933 (6.25e–19), FoxO-mediated apoptosis–KEGG:hsa05145 (2.85e–18) | MF: E-box binding (6.31e–9), BP: internal peptidyl-lysine acetylation (1.95e–6), MF: RNA polymerase II proximal promoter sequence-specific DNA binding (4.55e–10), BP: positive regulation of protein serine/threonine kinase activity (4.97e–10), BP: activation of protein kinase activity (6.94e–9) |
| Genistein   | ESR1, ESR2, CFTR, CASP3, TNF, PGR, CYP1A1, MAPK3, MAPK1, PTGS | Immune System–REACT:R-HSA-168256 (2.97e–210), Metabolism–REACT:R-HSA-1430728 (6.69e–207), Signal Transduction–REACT:R-HSA-162582 (9.81e–201), Innate Immune System–REACT:R-HSA-168249 (1.01e–158), Pathways in cancer–KEGG:hsa05200 (3.10e–137) | BP: positive regulation of cytosolic calcium ion concentration (4.38e–31), BP: cytosolic calcium ion transport (3.97e–19), BP: glucose import (2.80e–14), BP: iron homeostasis (3.87e–12), BP: T-helper cell differentiation (4.24e–12) |
Conclusions
The phenolics have already been reported to have significant anti-cancer potential. Here, we further explored them for their mechanistic perspective as potential anti-cancer lead molecules for CSC genes. Computationally, a bipartite graph has been formed where one group is the set of collected CSC genes and the other group is the interacting phenolics. The edges represent the interactions and are weighted according to the strength of interaction between the phenolics and the CSC genes. Also, the CSC genes are given some weight by two metrics, namely, DSI and DPI. Then, a ranking technique inspired from PR algorithm has been developed to rank the phenolics. However, one can apply other ranking algorithms (e.g., matrix factorization) to rank the phenolics. The
ranks of the phenolics indicate their association with the CSC genes. From data collection to validation, several databases have been used. In this study, few phytochemicals have been tested and validated for their strong effects on CSCs. Further efforts should be made to experimentally validate their potential to target CSCs, toxicities and drug-abilities. The associated pathways for all the top ranked phenolics are related to cancer,
immune system, metabolic, signal transduction etc. Moreover, the low $p$-values associated with the pathways indicate the statistical significance of the phenolics to those pathways. Lower $p$-values of the GO-terms indicate that the resultant phenolics are statistically significant and are not selected randomly and it is evident from the table. As future work, we will extend our work through including the combinations of the drugs targeting different CSC-genes into our current study, as well as collecting more data for a larger number of phenolics.

**Abbreviations**

CSCs: Cancer stem cells; DSI: Disease specificity index; DPI: Disease pleiotropy index; PR: PageRank; PSA: Polar surface area; HBA: Hydrogen bond (H-Bond) acceptors; HBD: Hydrogen bond (H-Bond) donors; BBB: Blood–brain-barrier.
Acknowledgements
We thank the members in Bioinformatics and Systems Medicine Laboratory and Institute of Life Science Laboratory for the useful discussion and valuable suggestions.

About this supplement
This article has been published as part of BMC Bioinformatics Volume 21 Supplement 21 2020: Accelerating Bioinformatics Research with ICIBM 2020. The full contents of the supplement are available at https://bmcbioinformatics.biomedcentral.com/articles/supplements/volume21-supplement-21.

Authors’ contributions
MM, SKS, PP and SM developed and implemented the proposed methodology, carried out experiments, written and revised the manuscript. ZZ conceived the project and participated in manuscript writing and revision. All authors read and approved the final manuscript.

Funding
This research was partially supported by the Cancer Prevention and Research Institute of Texas (CPRIT RP170668 and RP180734) to ZZ. Publications costs are funded by Dr. Zhao’s Professorship Fund. The funder had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. MM was partially supported by TARE scheme of DST-SERB, Govt. of India.

Availability of data and materials
The following publicly available databases have been used in this study namely CSCdb database (https://bioinformatics.usc.edu.cn/cscdb), PCIDB database (https://genome.jp/db/pcidb), DisGeNET database (https://disgenet.org/), ChEMBL database (https://ebi.ac.uk/chembl), pkCSM database (https://biosig.unimelb.edu.au/pkcsms/) and CTD (https://ctdbase.org/).

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of School of Computer Science and Engineering, Xavier University, Bhubaneswar, Odisha 752050, India.
2 Institute of Life Sciences, Bhubaneswar, Odisha 751023, India. 3 Center for Precision Health, School of Biomedical Informatics, The University of Texas Health Science Center At Houston, Houston, TX 77030, USA. 4 Human Genetics Center, School of Public Health, The University of Texas Health Science Center At Houston, Houston, TX 77030, USA.

Received: 25 October 2020   Accepted: 27 October 2020
Published: 28 December 2020

References
1. Mattingly, C.J., Rosenstein, M.C., Colby, G.T., Forrest, J.N., Boyer, J.L.: Cancer and radiation therapy: Current advances and future directions. R. Baskar and K A Lee and R. Yeo and K-W Yeoh 9(03), 193–199 (2012)
2. Chen HHW, Kuo MT. Improving radiotherapy in cancer treatment: Promises and challenges. Oncotarget. 2017;8(37):62742–58.
3. Mallik S, Zhao Z. Identification of gene signatures from rna-seq data using pareto-optimal cluster algorithm. BMC Syst Biol. 2018a;12:21–9.
4. Bandyopadhyay S, Mallik S. Integrating multiple data sources for combinatorial marker discovery: A study in tumorigenesis. IEEE/ACM Trans Comput Biol Bioinf. 2018;15:673–87.
5. Mallik S, Zhao Z. Graph- and rule-based learning algorithms: A comprehensive review of their applications for cancer type classification and prognosis using genomic data. Brief Bioinform. 2018b;21:368–94.
6. Mallik S, Zhao Z. Congems: Condensed gene co-expression module discovery through rule-based learning and its application to lung squamous cell carcinoma. Genes. 2017;9:1–25.
7. Mallik S, Seth S, Bhadra T, Bandyopadhyay S. A linear regression and deep learning approach for detecting reliable genetic alterations in cancer using dna methylation and gene expression data. Genes. 2020;11:931.
8. Bhadra T, Mallik S, Bandyopadhyay S. Identification of multi-view gene modules using mutual information based hypograph mining. IEEE Trans Syst Man Cybernet Syst. 2019;49:1119–30.
9. Mallik S, Qin G, Jia P et al. Molecular signatures identified by integrating gene expression and methylation in non-seminoma and seminoma of testicular germ cell tumors. Epigenetics. 2020;13:1–15.
10. Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, Yan PS, Huang TH, Nephew KP. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Can Res. 2008;68(11):4311–20.
11. Ayob AZ, Ramasamy TS. The comparative toxicogenomics database (ctd): a resource for comparative toxicological studies. J Biomed Sci 25(20) (2018)
12. Tan BT, Park CY, Ailles LE, Weissman IL. The cancer stem cell hypothesis: a work in progress. Lab Invest. 2006;86:1203–7.
13. Shukla GKH, Srivastava AK, Khare PR, Saxena R. Therapeutic potential, challenges and future perspective of cancer stem cells in translational oncology: a critical review. Curr Stem Cell Res Ther. 2012;7(3):207–224.

14. Singh SK, Clarke ID, Teriyaki M. Identification of a cancer stem cell in human brain tumors. Can Res. 2003;63(18):5821–8.

15. Oh J, Hiatkyy L, Jeong Y-S, Kim D. Therapeutic effectiveness of anticancer phytochemicals on cancer stem cells. Toxins(Basel) 8(7), 199 (2016)

16. Mallick K, Mallik S, Bandyopadhyay S, Chakraborty S. A novel graph topology based go-similarity measure for signature detection from multi-omics data and its application to other problems. IEEE/ACM Trans Comput Biol Bioinform (2020 (Accepted)). doi: https://doi.org/10.1109/TCBB.2020.3020537

17. Mallick S, Bhadta T, Mallik U. Identifying epigenetic biomarkers using maximal relevance and minimal redundancy based feature selection for multi-omics data. IEEE Trans Nanobiosci. 2017;16:1–10.

18. Gaur P, Scussi EL, Samuel S, Xia L, Fan F, Zhou Y, Lu J, Tozzi F, Lopez-Berestein G, Vivas-Mejia P, Rashid A, Fleming, JR, Abdalla EK, Curley SA, Vauthey JN, Sood AK, Yao JC, Ellis LM. Identification of cancer stem cells in human gastrointestinal carcinoid and neuroendocrine tumors. Gastroenterology. 2011;141(5):1728–37.

19. Zhao J, Shi L, M Wu J, Wu C. The combination of systemic chemotherapy and local treatment may improve the survival of patients with unresectable metastatic colorectal cancer. Mol Clin Oncol. 2017;6(6):856–60.

20. Agli M, Naqui JR, Mallick S, et al. The hir nef protein modulates cellular and exosomal mirna profiles in human monocyteic cells. J Extracell Vesiclus. 2014;3:1–12.

21. Qin G, Mallick-RMS, et al. Microma and transcription factor co-regulatory networks and subtype classification of seminoma and non-seminoma in testicular germ cell tumors. Nat Sci Rep. 2020;10:1–14.

22. Liskova A, Kubatka P, Samec M, Zubor P, Mlynec M, Bielik T, Samuel SM, Zulli A, Kwon TK, Busselberg D. Dietary phytochemicals targeting cancer stem cells. Molecules 24(5), 899 (2019)

23. Shen Y, Yao H, Li A, Wang M. Cscdb: a cancer stem cells portal for markers, related genes and functional information. Comput Biol Chem 2016; baw023 (2016)

24. Mosely J, Sinivilasan S, Anikem MK, Damodatan C. Natural products that target cancer stem cells. Anticancer Res. 2015;35:5773–88.

25. Dandawate P, Subramaniam D, Jensen R, Anant S. Targeting cancer stem cells and signaling pathways by phytochemicals: novel approach for breast cancer therapy. Semin Cancer Biol. 2004;40:41-192–208. 

26. Pcidb- phytochemical interactions database https ://www.genom e.jp/db/pcidb

27. Chan M, Chen R, Fong D. Targeting cancer stem cells with dietary phytochemical - repositioned drug combinations. Cancer Lett. 2018;453:53–64.

28. Pinerio JB, Queralt-Rosinach N, Gutierrez-Sacrist‘an A, Deu-Pors J, Centeno E, Garcia-Garcia J, Sanz F, Furlong L. Disgenet: a comprehensive platform integrating information on human disease-associated genes and variants. Nucleic Acids Res 4(45), 10–10934327924018 (2017)

29. Brin S, Page L. The anatomy of a large-scale hyperntextual web search engine. Comput Netw ISDN Syst. 2020;4:107–17.

30. Gaulton A, Bellis L, Bento A, Chambers J, Davies M, Hersey A. Chembl: a largescale bioactivity database for drug discovery. Nucleic Acids Res. 2012;40:10–109377721948594.

31. Daniel FV, Stephen RI, Cheng H-Y, Brian RS, Keith WW, Kenneth DK. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem. 2002;45(12):2615–23.

32. Ritchie TJ, Macdonald SJF. The impact of aromatic ring count on compound developability – are too many aromatic rings a liability in drug design? Drug Discov Today 14(21–22) (2009)

33. Whitlock NC, Baek SJ. The anticancer effects of resveratrol-modulation of transcription factors. Nutr Cancer. 2012;64(4):493–502.

34. Lopez-Lazaro M. Anticancer and carcinogenic properties of curcumin: considerations for its clinical development as a cancer chemopreventive and chemotherapeutic agent. Mol Nutrit Food Res. 2008;52(S1):103–27.

35. Goel A, Aggarwal B. Curcumin, the golden spice from indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. Nutr Cancer. 2010;62(7):919–30.

36. Srivastava S, Somasagara R, et al. Quercetin, a natural flavonoid interacts with dna, arrests cell cycle and causes apoptosis. Mol Nutrit Food Res. 2008;52(S1):103–27.

37. Rady J, Mohamed H, Rady M, Siddiqi IA, Mukhtar H. Cancer preventive and therapeutic effects of egcg, the major polyphenol in green tea. Egypt J Basic Appl Sci 5(1), 1–23 (2018)

38. Spagnuolo C, Russo GL, Orhan IE, Habtemariam S, Daglia M, Sureda A, Nabavi SF, Devi KP, Loizzo MR, Tundis R, Nabavi SM. Genistein and cancer: current status, challenges, and future directions. Adv Nutrit. 2015;6(4):408–19.

39. Pines DE, Blundell TL, Ascher DB. pkcsm: Predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. J Med Chem. 2015;58(9):4066–72.

40. Mattingly CJ, Rosenstein MC, Colby GT, Forrest JN, Boyer JL. The comparative toxicogenomics database (ctd): a resource for comparative toxicological studies. J Exp Zool Part A Comp Exp Biol. 2006;305(9):689–92.

41. Mashima T. Cancer stem cells (cscs) as a rational therapeutic cancer target, and screening for csc-targeting drugs. Yakugaku Zasshi. 2003;63(18):5821–8.

42. Shoham S, Leicht S, Givol D, Yabuuchi H, Arakawa T, et al. Cancer stem cell targeting: a new strategy for cancer treatment. Nature Rev Cancer. 2019;19(11):1–18.

43. Larzabal L, El-Nikhely N, Redrado M, et al. Differential effects of drugs targeting cancer stem cell (csc) and non-csc populations on lung primary tumors and metastasis. Cancers (Basel). 2015;8(11):1–13.

44. Saygin C, Matei D, Majeti R, et al. Targeting cancer stemness in the clinic: From hype to hope. Cell Stem Cell. 2019;24:25–40.